Why Isolators Do Not Automatically Ensure Annex 1 Compliance

By Juergen M. Metzger, Pharma-Technology-Consulting, LLC

In many aseptic fill/finish projects, especially in small molecule manufacturing (vials, syringes, and lyophilized products), the decision to use an isolator is often treated as a shortcut to GMP compliance.

The logic seems straightforward: isolators provide physical separation, support high sterility assurance levels (SAL), and allow for reproducible biodecontamination. Therefore, they must represent the safest — and most compliant — solution. In reality, this assumption is often wrong.

Isolators are powerful tools, but they do not automatically ensure compliance with EU GMP Annex 1. However, RABS — particularly modern active RABS concepts operated under a robust contamination control strategy — are frequently dismissed too quickly, even though they can fully meet Annex 1 expectations when properly designed, implemented, and operated; the difference is not the technology itself, but how it is applied.

The Misconception: Technology = Compliance

The preference for isolators is usually driven by risk reduction — and, to be honest, by the desire to simplify justification.

Compared to open systems, isolators clearly offer advantages (e.g., defined separation, controlled environment, reproducible vaporized hydrogen peroxide (VHP) cycles), but problems start when the isolator decision is made too early, before the process, the facility, and the operational reality are fully defined. In those cases, the isolator becomes a perceived “compliance shortcut.” Material transfer, intervention concepts, maintenance access, and even environmental monitoring are often addressed later, sometimes during factory acceptance testing (FAT) or even site acceptance testing (SAT). At that point, options are limited, and compromises begin. On paper, the system may look compliant. In operation, it often tells a different story.

Annex 1 does not assess technology in isolation. It assesses how well contamination is controlled across the entire process.

Where Isolator Projects Actually Run Into Problems

The issues seen in isolator-based systems are rarely caused by the isolator itself. They are almost always caused by how the system is designed and integrated, especially in typical small molecule setups with high throughput and frequent interventions.

1. Transfer Concepts That Look Good But Don’t Work In Reality

Material transfer is one of the biggest contamination risks in any aseptic process. Rapid transfer ports (RTPs), alpha-beta systems, and transfer chambers are standard, but that doesn’t mean they are properly integrated.

Typical issues include:

• insufficient decontamination at transfer interfaces
• too many manual steps
• transfer frequency not aligned with cycle capability.

In high-output vial or syringe lines, this becomes critical very quickly. If transfer is not robust, the isolator does not compensate for it.

2. Biodecontamination Is Treated As “Standard”

VHP cycles are often assumed to be a solved topic or, even worse, as a substitute for proper cleaning before closing the isolator and the VHP cycle starts. They are not. In reality, performance depends heavily on:

• isolator geometry and aseptic design (e.g., radii, corner design, surface finish)
• load configuration (e.g., nested syringes, stoppers, lyo loads)
• airflow distribution
• material compatibility.

Common gaps are:

• shadowing in complex layouts
• different behavior between empty vs. loaded conditions
• aeration not aligned with production timelines.

Without proper development, including integrated mockups, early computational fluid dynamics (CFD) and smoke studies, and rigorous testing together with the filling line, and worst-case validation (already defined well before FAT), the isolator environment is often far less controlled than assumed.

3. Operational Reality Is Underestimated

This is where many systems start to drift. In small molecule production, frequent format changes, interventions, glove use, maintenance access, and line clearance activities are part of routine operations. These activities are not exceptional events; they define the operational reality of aseptic manufacturing. Typical issues are:

• intervention frequency not reflected in risk assessments
• maintenance requiring system breaks or workarounds
• procedures that look good on paper but are difficult to execute consistently.

If operations are not considered early, the system will struggle later, no matter how good the isolator is.

4. Integration With The Facility Is Weak

An isolator is not a stand-alone solution. It must work together with the HVAC, room classification, material and personnel flows, and upstream and downstream processes (e.g., washing, depyrogenation, lyophilization). Typical gaps are:

• mismatch between isolator concept and background environment
• inefficient material flows
• disconnect between equipment and facility layout.

Annex 1 expects a holistic system. Weak interfaces will always show up sooner or later.

Why RABS Are Often Misjudged

RABS are often seen as the second choice. That’s an oversimplification. When especially active RABS are treated like an isolator in operation, they provide physical separation, defined airflow, and restricted operator access. They do not offer the same level of enclosure as isolators, but that does not automatically make them noncompliant.

The key factor is not the technology; it is how consistently it is controlled. A well-designed and well-operated RABS can meet Annex 1 expectations if:

• interventions are minimized and controlled (that means glove operations and RTP use)
• airflow conditions are stable
• procedures are robust and followed.

On the other hand, a poorly implemented isolator can fail for the exact same reasons. Annex 1 does not prescribe isolators. It requires justified, effective contamination control.

The Real Driver: Contamination Control Strategy (CCS)

The revised Annex 1 makes one thing very clear: Compliance is based on the Contamination Control Strategy, not on equipment selection.

The CCS defines how risks are identified, how they are controlled, how they are monitored, and how they are continuously reviewed. This includes facility design, equipment, transfer systems, cleaning and disinfection, environmental monitoring, interventions, and maintenance.

The choice between isolator and RABS should come out of this strategy, not the other way around. If the CCS is solid, both technologies can work. If it is not, neither will perform as expected.

Practical Considerations

From a project perspective, a few points make a significant difference:

• Define the CCS first, not last
  Barrier technology should be the result of the strategy — not the starting point.
• Treat transfer as a primary risk driver
  This applies especially in high-volume vial and syringe lines.
• Develop biodecontamination based on reality
  Include worst-case loads and configurations.
• Design for operations, not for drawings
  Consider interventions, maintenance, and changeovers early.
• Integrate equipment and facility as one system
  Avoid late-stage compromises.
• Avoid default decisions
  “We always use isolators” is not a strategy.

So, What Does This Mean In Practice?

There is no question that isolators are highly effective and often the most future-proof solution. When evaluated holistically — including contamination control, operational efficiency, labor requirements, and long-term compliance expectations — they may also provide a faster return on investment and a shorter break-even period in many applications, but they are not a guarantee for Annex 1 compliance. Well-designed active RABS concepts, whether open or closed, are not inherently non-compliant and can fully meet Annex 1 expectations when properly implemented. Both technologies can succeed or fail depending on how they are applied. In the end, compliance is not driven by the choice of barrier system, but by how well contamination risks are understood, controlled, and managed across the entire process.

About The Author:

Juergen M. Metzger is founder and principal of Pharma-Technology-Consulting, LLC, specializing in aseptic fill-finish, containment systems, and Annex 1 compliance. He has nearly 30 years of experience in the pharmaceutical manufacturing industry, with a focus on isolator technology, aseptic processing, and contamination control strategies. He began his career with Bosch Packaging Technology in 1999 and has held technical and leadership roles across engineering, product management, and global project coordination. He has worked extensively on aseptic fill-finish systems worldwide, supporting the design, implementation, and optimization of complex manufacturing environments.